Titan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPFree Report) in a report released on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ TTNP opened at $4.42 on Friday. Titan Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $14.80. The business’s 50 day moving average is $4.92 and its two-hundred day moving average is $5.75.

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) last announced its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.

About Titan Pharmaceuticals

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Read More

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.